Wausau, WI (PRWEB) December 03, 2015
UAS Laboratories is proud to announce the publication of a study in the European Journal of Clinical Nutrition on the role of short-term use of their Junior formula containing L. acidophilus DDS®-1 and B. lactis UABla-12™ in supporting respiratory tract health in children. This is the second clinical study on this formulation. The first study, published in 2010, looked at benefits for skin health in children.
“Evidence is mounting regarding the role probiotics can play in the health of children, with many studies pointing to supporting respiratory health during longer-term probiotic administration. This study is unique in that it evaluated the effect of a finished commercial product instead of only an active ingredient, and it looked at a short-term, acute administration to a healthy child on the first day of the appearance of a sick household member. It’s remarkable that this acute administration of the probiotic to healthy kids resulted in significant benefits to the respiratory health in children. We’re thrilled to add to the body of evidence on probiotic benefits with two clinical studies to support our Junior formula,” stated Dr. Greg Leyer, Chief Scientific Officer at UAS Labs.
The study concluded the short-term use of probiotics supports upper respiratory tract health in preschool and elementary school aged children. The complete study can be accessed here: http://www.ncbi.nlm.nih.gov/pubmed/26463725 .
About UAS Laboratories:
Founded in 1979, UAS Labs, LLC, has delivered the highest quality, science-backed probiotics to the natural products marketplace for more than thirty years. Strictly dedicated to probiotic manufacturing, UAS Labs is committed to designing innovative and effective formulations including strains such as L. acidophilus DDS®-1 and patent-pending LRC™ for cholesterol support. UAS Labs’ products are sold to private label and contract manufacturing customers in the U.S., Canada, and over 45 other countries. Dr. Gregory Leyer received his PhD in Food Microbiology and Toxicology from the University of Wisconsin - Madison. He is a professional member of both the IPA and ISAPP and has co-authored several papers in the areas of probiotic clinical results, application know-how, and safety parameters.